Antiviral agent.
ATX code: J05AX.
Pharmacological properties
Pharmacodynamics
The active substance of the drug TRIAZAVIRIN
sup>® – riamilovir is a synthetic analog of purine nucleoside bases (guanine) with expressed antiviral action. It has a broad spectrum of antiviral activity against RNA-containing viruses.
The basic mechanism of action of the preparation TRIAZAVIRIN ® is inhibition of synthesis of viral RNA and replication of genomic fragments.
Pharmacokinetics
After oral administration, it is rapidly absorbed in the gastrointestinal tract. Maximum concentration (Cmax) is reached on average in 1-1.5 h. Cmax with the recommended dosing regimen is on average 4.8 µg/ml. Blood AUC (area under the pharmacokinetic curve “concentration – time”) is 12.8 µg/h*ml. The elimination half-life (T1/2) is 1-1.5 h. 15 to 45% of riamilovir is excreted unchanged by the kidneys. The average value of estimated clearance is 246 ml/min.
Indications
As part of the complex therapy of influenza and other acute respiratory viral infections in adult patients.
Active ingredient
Riamilovir
Composition
Solid gelatin capsules size #1, yellow body and red cap. The contents of the capsules are fine crystalline powder or pellets of yellow or yellow-green color.
How to take, the dosage
Triazavirin® is taken orally with plenty of drinking water, regardless of meals. The capsule should be swallowed whole; it is not recommended to chew or crush the capsule.
The drug should be started not later than the 2nd day after the beginning of the disease (manifestation of clinical symptoms of flu and other acute respiratory viral infections).
The recommended dose:
in influenza and other acute respiratory viral infections: 1 capsule (250 mg)
3 times a day for 5 consecutive days.
Maximum single dose: 1 capsule (250 mg). Maximum daily dose: 3 capsules (750 mg).
If within 5 days of treatment there is no improvement, or if symptoms worsen, or new symptoms develop, you should consult a physician. Use only with the directions, route of administration, and dosage listed.
Interaction
Special clinical trials to study the interaction with other medicinal products have not been conducted. If you use any medicines (including over-the-counter ones), consult your doctor before using the medicinal product TRIAZAVIRIN®.
Special Instructions
The drug TRIAZAVIRIN® contains the dyes sunset yellow (E110) and azorubin (E122), which may cause allergic reactions.
Influence on the ability to drive vehicles, mechanisms
Have not been studied, but based on the spectrum of adverse reactions, no effect on these activities is expected.
Synopsis
Solid gelatin capsules size #1, yellow body and red cap. The contents of the capsules are fine crystalline powder or pellets of yellow or yellow-green color.
Contraindications
– Hypersensitivity to the drug components;
– Pregnancy;
– Breast-feeding period;
– Children under 18 years of age (effectiveness and safety have not been determined);
– Renal/liver failure (effectiveness and safety have not been determined).
Side effects
Disorders of the blood and lymphatic system: increased number of eosinophils in the blood.
Disorders of the immune system: allergic reactions (rash).
Nervous system disorders: headache.
Gastrointestinal tract disorders: dyspeptic phenomena (nausea, vomiting, bloating, pasty stools, flatulence, heartburn, abdominal pain, diarrhea, dry mouth).
Renal and urinary tract disorders: increase in urine red blood cells, white blood cells, squamous epithelium, presence of bacteria in the urine.
Laboratory and instrumental findings: Elevated plasma alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels.
General disorders and reactions at the site of administration: Sweakness.
If you experience or worsen the side effects listed in the instructions, or if you notice any other side effects not listed in the instructions, tell your doctor.
Overdose
Symptoms:nausea, vomiting, dyspeptic disorders, stomach pain.
Treatment:symptomatic therapy. If these symptoms occur, it is necessary to stop taking the drug and consult a physician.
Pregnancy use
Due to lack of strictly controlled studies in humans, the drug administration during pregnancy is contraindicated (see section “Contraindications”). Administration of the drug during breastfeeding has not been studied, therefore, if it is necessary to use the drug during lactation, breastfeeding should be stopped.
Weight | 0.013 kg |
---|---|
Shelf life | 5 years. Do not use after the expiration date. |
Conditions of storage | Store in a dark place at a temperature not exceeding 25 °С. Keep out of reach of children. |
Manufacturer | Medsintez plant, Russia |
Medication form | capsules |
Brand | Medsintez plant |
Other forms…
Related products
Buy Triazavirin, 250 mg capsules 10 pcs with delivery to USA, UK, Europe and over 120 other countries.